Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.

[1]  A. Drilon,et al.  539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study , 2020 .

[2]  M. Hellmich,et al.  Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  R. Herbst,et al.  Health‐Related Quality of Life in KEYNOTE‐010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  P. Fayers,et al.  General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. , 2019, European journal of cancer.

[5]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[6]  L. Constine,et al.  New Agents, Emerging Late Effects, and the Development of Precision Survivorship. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jaap C. Reijneveld,et al.  Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire , 2018, Health and Quality of Life Outcomes.

[8]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[9]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[10]  D. Bota,et al.  Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients , 2018, Expert review of quality of life in cancer care.

[11]  A. Tafreshi,et al.  Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. , 2017, The Lancet. Oncology.

[12]  P. Hinds,et al.  Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint? , 2017, Cancer.

[13]  Marta Kulpa,et al.  Basic issues concerning health-related quality of life , 2017, Central European journal of urology.

[14]  H. Groen,et al.  Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Boutros,et al.  Current and Evolving Methods to Visualize Biological Data in Cancer Research. , 2016, Journal of the National Cancer Institute.

[16]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[17]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[19]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[20]  L. Howie,et al.  Early palliative care in cancer treatment: rationale, evidence and clinical implications , 2013, Therapeutic advances in medical oncology.

[21]  A. Adjei,et al.  Understanding, recognizing, and managing toxicities of targeted anticancer therapies , 2013, CA: a cancer journal for clinicians.

[22]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[23]  J. Varni,et al.  The PedsQL™ Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants , 2011, Quality of Life Research.

[24]  J. Woodcock,et al.  The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. , 2010, The oncologist.

[25]  P. Keegan,et al.  Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. , 2010, Journal of the National Cancer Institute.

[26]  D. Patrick,et al.  Patient-reported outcomes to support medical product labeling claims: FDA perspective. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[28]  A. Bottomley.  The cancer patient and quality of life. , 2002, The oncologist.

[29]  Michael Seid,et al.  PedsQL™ 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in Healthy and Patient Populations , 2001, Medical care.

[30]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.